This content is in French.
Triple-negative: a new targeted weapon?
28 octobre 2025
By Ana Espino | Published on October 28, 2025 | 3 min readTriple-negative breast cancer (TNBC) accounts for about 15% of all breast cancers. Its prognosis is poor, particularly in the metastatic stage. Its biology—characterized by the absence of hormone receptors (ER, PR) and HER2—limits the effectiveness of conventional targeted therapies. In addition, recurrence is common, and patients have few
Triple-negative breast cancer (TNBC) accounts for about 15% of all breast cancers. Its prognosis is poor, particularly in the metastatic stage. Its biology—characterized by the absence of hormone receptors (ER, PR) and HER2—limits the effectiveness of conventional targeted therapies. In addition, recurrence is common, and patients have few therapeutic options after the first lines of chemotherapy, which are often taxane-based.
Among the potential therapeutic approaches, the PI3K/AKT/PTEN pathway, which is frequently altered in these tumors, could represent a promising target. Ipatasertib, an oral selective AKT inhibitor, has already shown some efficacy, particularly when combined with paclitaxel. However, taxane-related toxicities can limit their use.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
: López-Miranda, E., et al. (2025). Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial. Breast cancer research : BCR, 27(1), 141
View the source
